International Journal of Clinical Research
International Journal of Clinical Research. 2022; 6: (2) ; 10.12208/j.ijcr.20220023 .
总浏览量: 754
华中科技大学同济医学院附属协和医院消化内科 湖北武汉
*通讯作者： 楚慧款,单位：华中科技大学同济医学院附属协和医院消化内科 湖北武汉；
肠易激综合征（irritable bowel syndrome，IBS）是一种常见的功能性肠病，其特征是反复发作的腹痛或腹胀，伴随大便次数和性状改变。最近的研究表明肠道菌群在调节宿主免疫及炎症性疾病的发生和发展中起着重要作用，低水平的炎症会促进真菌定植，而真菌定植则会促进进一步的炎症。免疫激活和炎症反应在IBS的病理机制中十分重要。有研究发现白色念珠菌可以通过念珠菌溶素激活宿主免疫反应、影响紧密连接蛋白的表达、破坏细胞，致使上皮通透性增加和屏障功能被破坏。现阶段IBS治疗方法局限，并且其相关症状显著影响患者的生活质量，因此阐明IBS的机制十分重要。本文综述了近年来国内外对肠道细菌和真菌与IBS关系的研究，旨在为进一步明确IBS的发病机制及找到有效的干预方法提供理论基础。
Irritable bowel syndrome (IBS) is a common functional bowel disease characterized by recurrent abdominal pain or bloating, accompanied by changes in the frequency and characteristics of bowel movements. Recent studies have shown that the intestinal microbiome plays an important role in regulating host immunity and the occurrence and development of inflammatory diseases. Low-level inflammation promotes fungal colonization, and it promotes further inflammation. Immune activation and inflammation are very important in the pathogenesis of IBS. Studies have found that Candida albicans can activate the host immune response through candidalysin, affect the expression of tight junction proteins, and destroy cells, resulting in increased epithelial permeability and destruction of barrier function. At this stage, the treatment of IBS is limited, and its related symptoms significantly affect the quality of life of patients, so it is very important to clarify the mechanism of IBS. This article reviews recent studies on the relationship between intestinal bacteria/fungi and IBS in China and the other countries, aiming to provide a theoretical basis for further clarifying the pathogenesis of IBS and finding effective intervention methods.
[1] Sperber A D, Dumitrascu D, Fukudo S, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review[J]. Gut,2017,66(6):1075-1082.
[2] Quigley E M, Abdel-Hamid H, Barbara G, et al. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome[J]. J Clin Gastroenterol,2012,46(5):356-366.
[3] Fond G, Loundou A, Hamdani N, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis[J]. Eur Arch Psychiatry Clin Neurosci,2014,264(8):651-660.
[4] Ghoshal UC, Shukla R, Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut Liver. 2017;11(2):196-208.
[5] Ghoshal U C, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype[J]. World J Gastroenterol, 2014,20(10):2482-2491.
[6] Chatterjee S, Park S, Low K, et al. The degree of breath methane production in IBS correlates with the severity of constipation[J]. Am J Gastroenterol,2007,102(4):837-841.
[7] Lupp C, Robertson M L, Wickham M E, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae[J]. Cell Host Microbe, 2007, 2(2): 119-129.
[8] Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47(6):804-811.
[9] Giuliano M, Barza M, Jacobus N V, et al. Effect of broad-spectrum parenteral antibiotics on composition of intestinal microflora of humans[J]. Antimicrob Agents Chemother,1987,31(2):202-206.
[10] Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017; 152(5): 1042-1054.e1
[11] De Giorgio R, Volta U, Gibson P R. Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?[J]. Gut,2016,65(1):169-178.
[12] Weig M, Werner E, Frosch M, et al. Limited effect of refined carbohydrate dietary supplementation on colonization of the gastrointestinal tract of healthy subjects by Candida albicans[J]. Am J Clin Nutr, 1999, 69(6): 1170-1173.
[13] Frese S A, Benson A K, Tannock G W, et al. The evolution of host specialization in the vertebrate gut symbiont Lactobacillus reuteri[J]. PLoS Genet,2011,7(2):e1001314.
[14] Hyland N P, Quigley E M, Brint E. Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions[J]. World J Gastroenterol,2014,20(27):8859-8866.
[15] Goto Y, Ivanov I I. Intestinal epithelial cells as mediators of the commensal-host immune crosstalk[J]. Immunol Cell Biol,2013,91(3):204-214.
[16] Bertiaux-Vandaele N, Youmba S B, Belmonte L, et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype[J]. Am J Gastroenterol,2011,106(12):2165-2173.
[17] Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome[J]. Gastroenterology, 2007,132(1):26-37.
[18] Abreu M T. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function[J]. Nat Rev Immunol,2010,10(2):131-144.
[19] Wang Y, Devkota S, Musch M W, et al. Regional mucosa-associated microbiota determine physiological expression of TLR2 and TLR4 in murine colon[J]. PLoS One,2010,5(10):e13607.
[20] Tattoli I, Petitta C, Scirocco A, et al. Microbiota, innate immune system, and gastrointestinal muscle: ongoing studies[J]. J Clin Gastroenterol,2012,46 Suppl:S6-S11.
[21] Petersson J, Schreiber O, Hansson G C, et al. Importance and regulation of the colonic mucus barrier in a mouse model of colitis[J]. Am J Physiol Gastrointest Liver Physiol,2011,300(2):G327-G333.
[22] Gareau M G, Jury J, Macqueen G, et al. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation[J]. Gut,2007,56(11):1522-1528.
[23] Buckley M M, O'Mahony S M, O'Malley D. Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome[J]. World J Gastroenterol,2014,20(27):8846-8858.
[24] Wedlake L, A'Hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome[J]. Aliment Pharmacol Ther,2009,30(7):707-717.
[25] Appleby R N, Walters J R. The role of bile acids in functional GI disorders[J]. Neurogastroenterol Motil, 2014, 26(8): 1057-1069.
[26] Kumamoto C A. Inflammation and gastrointestinal Candida colonization[J]. Curr Opin Microbiol, 2011, 14(4): 386-391.
[27] Pappas P G, Lionakis M S, Arendrup M C, et al. Invasive candidiasis[J]. Nat Rev Dis Primers,2018,4:18026.
[28] Ho J, Yang X, Nikou SA, et al. Candidalysin activates innate epithelial immune responses via epidermal growth factor receptor. Nat Commun. 2019;10(1):2297.
[29] Petitpierre M, Gumowski P, Girard J P. Irritable bowel syndrome and hypersensitivity to food[J]. Ann Allergy, 1985, 54(6):538-540.
[30] Santelmann H, Howard J M. Yeast metabolic products, yeast antigens and yeasts as possible triggers for irritable bowel syndrome[J]. Eur J Gastroenterol Hepatol, 2005, 17(1): 21-26.
[31] Hong G, Li Y, Yang M, et al. Gut fungal dysbiosis and altered bacterial-fungal interaction in patients with diarrhea-predominant irritable bowel syndrome:An explorative study[J]. Neurogastroenterol Motil, 2020, 32(11):e13891.
[32] Sokol H, Leducq V, Aschard H, et al. Fungal microbiota dysbiosis in IBD. Gut. 2017;66(6):1039-1048.
[33] Spiller R, Pelerin F, Cayzeele D A, et al. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation[J]. United European Gastroenterol J, 2016,4(3):353-362.
[34] Cruz-Aguliar R M, Wantia N, Clavel T, et al. An Open-Labeled Study on Fecal Microbiota Transfer in Irritable Bowel Syndrome Patients Reveals Improvement in Abdominal Pain Associated with the Relative Abundance of Akkermansia Muciniphila[J]. Digestion, 2019, 100(2):127-138.
[35] Allert S, Förster TM, Svensson CM, et al. Candida albicans-Induced Epithelial Damage Mediates Translocation through Intestinal Barriers. mBio. 2018; 9(3): e00915-18.
[36] Sheil B, Mccarthy J, O'Mahony L, et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis[J]. Gut, 2004, 53(5): 694-700.
[37] Botschuijver S, Roeselers G, Levin E, et al. Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats[J]. Gastroenterology, 2017, 153(4): 1026-1039.
[38] Netea M G, Gow N A, Munro C A, et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors[J]. J Clin Invest,2006,116(6):1642-1650.
[39] Kumamoto C A. Inflammation and gastrointestinal Candida colonization[J]. Curr Opin Microbiol, 2011, 14(4): 386-391.
[40] Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014 Oct;109(10):1547-61; quiz 1546, 1562.
[41] Zeng J, Li Y Q, Zuo X L, et al. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2008, 28(8): 994-1002.
[42] Pimentel M, Lembo A, Chey W D, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation[J]. N Engl J Med,2011,364(1):22-32.
[43] Pimentel M, Chow E J, Lin H C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study[J]. Am J Gastroenterol, 2003,98(2):412-419.
[44] Richardson JP, Mogavero S, Moyes DL, et al. Processing of Candida albicans Ece1p Is Critical for Candidalysin Maturation and Fungal Virulence. mBio. 2018; 9(1): e02178-17.
[45] Moyes D L, Wilson D, Richardson J P, et al. Candidalysin is a fungal peptide toxin critical for mucosal infection[J]. Nature,2016,532(7597):64-68.
[46] Wilson D, Naglik JR, Hube B. The Missing Link between Candida albicans Hyphal Morphogenesis and Host Cell Damage. PLoS Pathog. 2016;12(10):e1005867.
[47] Naglik J R, Gaffen S L, Hube B. Candidalysin: discovery and function in Candida albicans infections[J]. Curr Opin Microbiol,2019,52:100-109.
[48] Ho J, Yang X, Nikou S A, et al. Candidalysin activates innate epithelial immune responses via epidermal growth factor receptor[J]. Nat Commun,2019,10(1):2297.
[49] Kasper L, Konig A, Koenig P A, et al. The fungal peptide toxin Candidalysin activates the NLRP3 inflammasome and causes cytolysis in mononuclear phagocytes[J]. Nat Commun,2018,9(1):4260.
[50] Verma AH, Richardson JP, Zhou C, et al. Oral epithelial cells orchestrate innate type 17 responses to Candida albicans through the virulence factor candidalysin. Sci Immunol. 2017;2(17):eaam8834.
[51] Radziwon C D, Lackner J M. Cognitive Behavioral Therapy for IBS: How Useful, How Often, and How Does It Work?[J]. Curr Gastroenterol Rep,2017,19(10):49.
[52] Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life [published correction appears in J Clin Gastroenterol. 2011 Oct; 45(9): 838]. J Clin Gastroenterol. 2011; 45(8): 679-683.
[53] Bafutto M, Almeida JR, Leite NV, Costa MB, Oliveira EC, Resende-Filho J. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii. Arq Gastroenterol. 2013; 50(4): 304-309.
[54] Thompson J R. Is irritable bowel syndrome an infectious disease?[J]. World J Gastroenterol, 2016, 22(4): 1331- 1334.
[55] Zeng J, Li Y Q, Zuo X L, et al. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome[J]. Aliment Pharmacol Ther,2008,28(8): 994- 1002.
[56] Pimentel M, Lembo A, Chey W D, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation[J]. N Engl J Med,2011,364(1):22-32.
[57] Pimentel M, Chow E J, Lin H C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study[J]. Am J Gastroenterol, 2003, 98(2):412-419.
[58] Francino MP. Antibiotics and the human gut microbiome: Dysbioses and accumulation of resistances. Front Microbiol. 2015; 6: 1543.